|
NZ629898A
|
|
Compositions and methods for inhibition of cathepsins
|
|
CA2790407A1
|
|
Ophthalmic formulations
|
|
NZ597573A
|
|
Combretastatins for prevention of posterior capsule opacification
|
|
WO2010132498A1
|
|
Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy
|
|
WO2009129333A1
|
|
Methods for enhancing the efficacy of vascular disrupting agents
|
|
WO2009103076A1
|
|
Methods and compositions for enhancing the efficacy of rtk inhibitors
|
|
WO2009067706A1
|
|
Method for treating hematopoietic neoplasms
|
|
US2009137687A1
|
|
Compositions and Methods With Enhanced Therapeutic Activity
|
|
AU2008202468A1
|
|
Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
|
|
WO2008109076A1
|
|
Methods for enhancing the efficacy of vascular disrupting agents
|
|
EP1835898A2
|
|
Methods for modulating tumor growth and metastasis
|
|
AU2004296805A1
|
|
Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
|
|
AU2004201471A8
|
|
Compositions and Methods for Use in Targeting Vascular Destruction
|
|
EP1601348A2
|
|
Compositions and methods with enhanced therapeutic activity
|
|
US7358236B1
|
|
Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
|
|
NZ575466A
|
|
Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
|
|
IL159581D0
|
|
Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
|
|
MXPA04000386A
|
|
Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases.
|
|
AU2002246756A1
|
|
Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
|
|
WO0206279A1
|
|
Efficient method of synthesizing combretastatin a-4 prodrugs
|
